1254702-87-8
1254702-87-8 structure
- Name: Minnelide
- Chemical Name: Minnelide
- CAS Number: 1254702-87-8
- Molecular Formula: C21H25Na2O10P
- Molecular Weight: 514.37
- Catalog: Signaling Pathways Apoptosis Apoptosis
- Create Date: 2019-08-04 10:17:59
- Modify Date: 2025-08-25 11:06:27
-
Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide causes apoptotic[1].
| Name | Minnelide |
|---|
| Description | Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide causes apoptotic[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Minnelide (0-200 nM; 48 hours) shows significantly decreased cell viability in pancreatic cancer cell lines after treatment in the presence, but not in the absence, of phosphatase[2]. Cell Viability Assay[2] Cell Line: Pancreatic cancer cell line: S2-013, MIA PaCa-2, S2-VP10, and Panc-1 cells Concentration: 0.100 nM, 200 nM Incubation Time: 48 hours Result: Decreased cell viability of in vitro. |
| In Vivo | Minnelide (injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily) leads to a marked decrease in tumor weight and volume at the end of treatment and increases survival in orthotopic model of pancreatic cancer with MIA PaCa-2–derived human pancreatic tumors[2]. Minnelide (injection intraperitoneally; 0.42 mg/kg; once daily; 28 days) prevents locoregional spread and leads to a decrease in average tumor weight in a xenograft model of pancreatic cancer with metastatic S2-013 cells[2]. Minnelide (injection intraperitoneally; 0.42 mg/kg, 0.21 mg/kg; once daily) causes tumor regression and tumors from Minnelide-treated animals showed fibrosis and the presence of pyknotic nuclei in human pancreatic cancer xenografts in SCID mice[2]. Animal Model: Orthotopic model of pancreatic cancer with MIA PaCa 2-derived human pancreatic tumors in athymic nude mice[2] Dosage: 0.1-0.6 mg/kg Administration: Injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily Result: Prevented pancreatic tumor growth in vivo. Animal Model: Xenograft model of pancreatic cancer with metastatic S2-013 cell line in athymic nude mice[2] Dosage: 0.42 mg/kg Administration: Injection intraperitoneally; 0.42 mg/kg; once daily Result: Prevented extensive spread from the primary site of injection. Animal Model: Human pancreatic cancer xenografts in SCID mice[2] Dosage: 0.21 mg/kg, 0.42 mg/kg Administration: Injection intraperitoneally; 0.42 mg/kg; once daily Result: Reduced tumor burden in human xenografts from patients. |
| References |
| Molecular Formula | C21H25Na2O10P |
|---|---|
| Molecular Weight | 514.37 |